Clinical Trial Detail

NCT ID NCT01887886
Title A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating EGFR Mutation
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

lung non-small cell carcinoma

Therapies

Erlotinib + Onartuzumab

Age Groups: adult senior

No variant requirements are available.